{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:43:41Z","timestamp":1787024621525,"version":"build-2736575974"},"reference-count":23,"publisher":"Japanese Society of Internal Medicine","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2018,5,1]]},"DOI":"10.2169\/internalmedicine.9165-17","type":"journal-article","created":{"date-parts":[[2017,12,26]],"date-time":"2017-12-26T17:15:19Z","timestamp":1514308519000},"page":"1297-1300","source":"Crossref","is-referenced-by-count":20,"title":["Fatal Disseminated Tuberculosis during Treatment with Ruxolitinib Plus Prednisolone in a Patient with Primary Myelofibrosis: A Case Report and Review of the Literature"],"prefix":"10.2169","volume":"57","author":[{"given":"Yasuhiro","family":"Tsukamoto","sequence":"first","affiliation":[{"name":"Department of Hematology, Iizuka Hospital, Japan"},{"name":"Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Kiyasu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Iizuka Hospital, Japan"},{"name":"Department of Clinical Research Institute, National Kyushu Cancer Center, National Hospital Organization, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariko","family":"Tsuda","sequence":"additional","affiliation":[{"name":"Department of Hematology, Iizuka Hospital, Japan"},{"name":"Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motohiko","family":"Ikeda","sequence":"additional","affiliation":[{"name":"Department of Hematology, Iizuka Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motoaki","family":"Shiratsuchi","sequence":"additional","affiliation":[{"name":"Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Ogawa","sequence":"additional","affiliation":[{"name":"Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Yufu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Iizuka Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Tefferi A, Vainchenker W. Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies. J Clin Oncol 29: 573-582, 2011.","DOI":"10.1200\/JCO.2010.29.8711"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Vannucchi AM, Kantarjian HM, Kiladjian JJ, et al. A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis. Haematologica 100: 1139-1145, 2015.","DOI":"10.3324\/haematol.2014.119545"},{"key":"3","doi-asserted-by":"publisher","unstructured":"3. Heine A, Brossart P, Wolf D. Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis? Blood 122: 3843-3844, 2013.","DOI":"10.1182\/blood-2013-10-531103"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Gangat N, Caramazza D, Vaidya R, et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol 29: 392-397, 2011.","DOI":"10.1200\/JCO.2010.32.2446"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Yang JY, Han M, Koh Y, et al. Effects of corticosteroids on critically ill pulmonary tuberculosis patients with acute respiratory failure: a propensity analysis of mortality. Clin Infect Dis 63: 1449-1455, 2016.","DOI":"10.1093\/cid\/ciw616"},{"key":"6","unstructured":"6. Tassies D, Cervantes F, Nicolas JM, Feliu E, Soriano E, Rozman C. Tuberculosis in chronic myeloproliferative syndromes: its incidence and principle characteristics in a series of 562 patients. Med Clin (Barc) 96: 321-323, 1991."},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Polverelli N, Breccia M, Benevolo G, et al. Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients. Am J Hematol 92: 37-41, 2017.","DOI":"10.1002\/ajh.24572"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 366: 799-807, 2012.","DOI":"10.1056\/NEJMoa1110557"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 366: 787-798, 2012.","DOI":"10.1056\/NEJMoa1110556"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Al-Ali HK, Griesshammer M, le Coutre P, et al. Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial. Haematologica 101: 1065-1073, 2016.","DOI":"10.3324\/haematol.2016.143677"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Lee SC, Feenstra J, Georghiou PR. <i>Pneumocystis jiroveci<\/i> pneumonitis complicating ruxolitinib therapy. BMJ 2014 (Epub ahead of print).","DOI":"10.1136\/bcr-2014-204950"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Wysham NG, Sullivan DR, Allada G. An opportunistic infection associated with ruxolitinib, a novel janus kinase 1,2 inhibitor. Chest 143: 1478-1479, 2013.","DOI":"10.1378\/chest.12-1604"},{"key":"13","doi-asserted-by":"publisher","unstructured":"13. Caocci G, Murgia F, Podda L. Reactivation of hepatitis B virus infection following ruxolitinib treatment in a patient with myelofibrosis. Leukemia 28: 225-227, 2014.","DOI":"10.1038\/leu.2013.235"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Goldberg RA, Reichel E, Oshry LJ. Bilateral toxoplasmosis retinitis associated with ruxolitinib. N Engl J Med 369: 681-683, 2013.","DOI":"10.1056\/NEJMc1302895"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Vannucchi AM. Management of myelofibrosis. ASH Education Program Book 2011: 222-230, 2011.","DOI":"10.1182\/asheducation-2011.1.222"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America. (IDSA), September 1999, and the sections of this statement. Am J Respir Crit Care Med 161: 221-247, 2000.","DOI":"10.1164\/ajrccm.161.supplement_3.ats600"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Branco B, Metsu D, Dutertre M, et al. Use of rifampin for treatment of disseminated tuberculosis in a patient with primary myelofibrosis on ruxolitinib. Ann Hematol 95: 1207-1209, 2016.","DOI":"10.1007\/s00277-016-2684-0"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Chen YH, Lee CH, Pei SN. Pulmonary tuberculosis reactivation following ruxolitinib treatment in a patient with primary myelofibrosis. Leuk Lymphoma 56: 1528-1529, 2015.","DOI":"10.3109\/10428194.2014.963082"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Shamil E, Cunningham D, Wong BL. Ruxolitinib associated tuberculosis presenting as a neck lump. Case Rep in Infect dis 2015: 284168, 2015.","DOI":"10.1155\/2015\/284168"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Colomba C, Rubino R, Siracusa L, et al. Disseminated tuberculosis in a patient treated with a JAK2 selective inhibitor: a case report. BMC Res Notes 5: 552, 2012.","DOI":"10.1186\/1756-0500-5-552"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Palandri F, Polverelli N, Catani L. Ruxolitinib-associated tuberculosis: a case of successful ruxolitinib rechallenge. Ann Hematol 94: 519-520, 2015.","DOI":"10.1007\/s00277-014-2183-0"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Hopman RK, Lawrence SJ, Oh ST. Disseminated tuberculosis associated with ruxolitinib. Leukemia 28: 1750-1751, 2014.","DOI":"10.1038\/leu.2014.104"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Abidi MZ, Haque J, Varma P, et al. Reactivation of pulmonary tuberculosis following treatment of myelofibrosis with ruxolitinib. Case Rep Hematol 2016: 2389038, 2016.","DOI":"10.1155\/2016\/2389038"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/57\/9\/57_9165-17\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,5,4]],"date-time":"2018-05-04T23:32:47Z","timestamp":1525476767000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/57\/9\/57_9165-17\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,1]]},"references-count":23,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.9165-17","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,1]]}}}